Coronavirus disease 2019 (COVID-19) vaccine platforms: how novel platforms can prepare us for future pandemics: a narrative review
Open Access
- 30 April 2022
- journal article
- review article
- Published by Yeungnam University College of Medicine in Journal of Yeungnam Medical Science
- Vol. 39 (2), 89-97
- https://doi.org/10.12701/jyms.2021.01669
Abstract
More than 2 years after the explosion of the coronavirus disease 2019 (COVID-19) pandemic, extensive efforts have been made to develop safe and efficacious vaccines against infections with severe acute respiratory syndrome coronavirus 2. The pandemic has opened a new era of vaccine development based on next-generation platforms, including messenger RNA (mRNA)-based technologies, and paved the way for the future of mRNA-based therapeutics to provide protection against a wide range of infectious diseases. Multiple vaccines have been developed at an unprecedented pace to protect against COVID-19 worldwide. However, important knowledge gaps remain to be addressed, especially in terms of how vaccines induce immunogenicity and efficacy in those who are elderly. Here, we discuss the various vaccine platforms that have been utilized to combat COVID-19 and emphasize how these platforms can be a powerful tool to react quickly to future pandemics.Keywords
Funding Information
- National Research Foundation of Korea (2019R1A2C1005961)
- Ministry of Science, ICT and Future Planning
This publication has 53 references indexed in Scilit:
- Designing liposomal adjuvants for the next generation of vaccinesAdvanced Drug Delivery Reviews, 2016
- Single-dose administration of inactivated hepatitis A vaccination in the context of hepatitis A vaccine recommendationsInternational Journal of Infectious Diseases, 2013
- Matrix-M™ Adjuvant Induces Local Recruitment, Activation and Maturation of Central Immune Cells in Absence of AntigenPLOS ONE, 2012
- Adenoviruses: update on structure and functionJournal of General Virology, 2009
- DNA Vaccine UsingMycobacterium bovisAg85B Antigen Induces Partial Protection against Experimental Infection in BALB/c MiceClinical and Vaccine Immunology, 2006
- Development of rabies DNA vaccine using a recombinant plasmid.2005
- Adenoviruses as vaccine vectorsMolecular Therapy, 2004
- SARS — beginning to understand a new virusNature Reviews Microbiology, 2003
- A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancerCancer Gene Therapy, 2002
- Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccinesVaccine, 2000